Bioactivity and Glycosylation of Circulating Prolactin in Various Physiological and Pathological Conditions

Giovanna M. Gambino, Paolo Beck-Peccoz, Stefano Borgato, Giovanni Faglia, Anna Spada, Luca Persani

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Multiple posttranslational processes modify native PRL and result in the secretion of several PRL isoforms with different bioactivity. Since we observed that serum samples contain non-lactogenic substances able to interfere in Nb2 cell bioassay, in this study we extracted PRL molecules from sera of pregnant and non-pregnant normal adults, fetuses and patients with prolactinoma and evaluated the ability of partially purified PRL to stimulate Nb2 cell proliferation. The preliminary immunopurification of PRL samples, conferred good sensitivity and specificity to PRL biological assay. Whenever possible, bioactivity values were correlated with glycosylated-PRL levels (G-PRL), the major posttranslational modification known to reduce PRL bioactivity. The ratio of bioactive (B-) vs immunoreactive PRL (I-PRL) (B/I) in normal subjects was 0.9 ± 0.1 (mean ± SD), and not affected by TRH and sulpiride administration. PRL B/I ratio did not change during pregnancy, both in maternal (0.8 ± 0.1) and fetal circulation (1.0 ± 0.01). In patients with prolactinoma PRL B/I ratios (0.8 ± 0.18) were in the normal range. However, in 2 women with microprolactinoma, with a clear discrepancy between high I-PRL levels and mild clinical features, a significantly reduced PRL B/I ratio was observed (0.51 ± 0.08 and 0.52 ± 0.1 respectively). Conversely, a woman with clear clinical features of hyperprolactinemia, but border-line elevated I-PRL levels had a PRL B/I ratio in the upper limit of normal range. No variation in G-PRL vs NG-PRL percentages was observed in all the cases studied. In conclusion, our data show that physiological and pathological conditions of hyperprolactinemia, including fetal life, are associated in the majority of cases, with the secretion of PRL molecules with unchanged mitogenic activity on Nb2 cells. Nb2 PRL bioassay may be an useful tool to explain the discrepancies between clinical features and immunoreactive PRL levels in some particular cases.

Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalPituitary
Volume2
Issue number3
Publication statusPublished - 1999

Fingerprint

Prolactinoma
Glycosylation
Biological Assay
Prolactin
Hyperprolactinemia
Reference Values
Sulpiride
Post Translational Protein Processing
Serum
Protein Isoforms
Fetus
Mothers
Cell Proliferation
Sensitivity and Specificity
Pregnancy

Keywords

  • Fetuses
  • Glycosylated PRL
  • Nb2 rat lymphoma cells
  • Pregnancy
  • PRL bioactivity
  • PRL-secreting pituitary adenoma

ASJC Scopus subject areas

  • Endocrinology

Cite this

Gambino, G. M., Beck-Peccoz, P., Borgato, S., Faglia, G., Spada, A., & Persani, L. (1999). Bioactivity and Glycosylation of Circulating Prolactin in Various Physiological and Pathological Conditions. Pituitary, 2(3), 225-231.

Bioactivity and Glycosylation of Circulating Prolactin in Various Physiological and Pathological Conditions. / Gambino, Giovanna M.; Beck-Peccoz, Paolo; Borgato, Stefano; Faglia, Giovanni; Spada, Anna; Persani, Luca.

In: Pituitary, Vol. 2, No. 3, 1999, p. 225-231.

Research output: Contribution to journalArticle

Gambino, GM, Beck-Peccoz, P, Borgato, S, Faglia, G, Spada, A & Persani, L 1999, 'Bioactivity and Glycosylation of Circulating Prolactin in Various Physiological and Pathological Conditions', Pituitary, vol. 2, no. 3, pp. 225-231.
Gambino, Giovanna M. ; Beck-Peccoz, Paolo ; Borgato, Stefano ; Faglia, Giovanni ; Spada, Anna ; Persani, Luca. / Bioactivity and Glycosylation of Circulating Prolactin in Various Physiological and Pathological Conditions. In: Pituitary. 1999 ; Vol. 2, No. 3. pp. 225-231.
@article{f1ebb3ba6568447eb2753dabad6d5636,
title = "Bioactivity and Glycosylation of Circulating Prolactin in Various Physiological and Pathological Conditions",
abstract = "Multiple posttranslational processes modify native PRL and result in the secretion of several PRL isoforms with different bioactivity. Since we observed that serum samples contain non-lactogenic substances able to interfere in Nb2 cell bioassay, in this study we extracted PRL molecules from sera of pregnant and non-pregnant normal adults, fetuses and patients with prolactinoma and evaluated the ability of partially purified PRL to stimulate Nb2 cell proliferation. The preliminary immunopurification of PRL samples, conferred good sensitivity and specificity to PRL biological assay. Whenever possible, bioactivity values were correlated with glycosylated-PRL levels (G-PRL), the major posttranslational modification known to reduce PRL bioactivity. The ratio of bioactive (B-) vs immunoreactive PRL (I-PRL) (B/I) in normal subjects was 0.9 ± 0.1 (mean ± SD), and not affected by TRH and sulpiride administration. PRL B/I ratio did not change during pregnancy, both in maternal (0.8 ± 0.1) and fetal circulation (1.0 ± 0.01). In patients with prolactinoma PRL B/I ratios (0.8 ± 0.18) were in the normal range. However, in 2 women with microprolactinoma, with a clear discrepancy between high I-PRL levels and mild clinical features, a significantly reduced PRL B/I ratio was observed (0.51 ± 0.08 and 0.52 ± 0.1 respectively). Conversely, a woman with clear clinical features of hyperprolactinemia, but border-line elevated I-PRL levels had a PRL B/I ratio in the upper limit of normal range. No variation in G-PRL vs NG-PRL percentages was observed in all the cases studied. In conclusion, our data show that physiological and pathological conditions of hyperprolactinemia, including fetal life, are associated in the majority of cases, with the secretion of PRL molecules with unchanged mitogenic activity on Nb2 cells. Nb2 PRL bioassay may be an useful tool to explain the discrepancies between clinical features and immunoreactive PRL levels in some particular cases.",
keywords = "Fetuses, Glycosylated PRL, Nb2 rat lymphoma cells, Pregnancy, PRL bioactivity, PRL-secreting pituitary adenoma",
author = "Gambino, {Giovanna M.} and Paolo Beck-Peccoz and Stefano Borgato and Giovanni Faglia and Anna Spada and Luca Persani",
year = "1999",
language = "English",
volume = "2",
pages = "225--231",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Bioactivity and Glycosylation of Circulating Prolactin in Various Physiological and Pathological Conditions

AU - Gambino, Giovanna M.

AU - Beck-Peccoz, Paolo

AU - Borgato, Stefano

AU - Faglia, Giovanni

AU - Spada, Anna

AU - Persani, Luca

PY - 1999

Y1 - 1999

N2 - Multiple posttranslational processes modify native PRL and result in the secretion of several PRL isoforms with different bioactivity. Since we observed that serum samples contain non-lactogenic substances able to interfere in Nb2 cell bioassay, in this study we extracted PRL molecules from sera of pregnant and non-pregnant normal adults, fetuses and patients with prolactinoma and evaluated the ability of partially purified PRL to stimulate Nb2 cell proliferation. The preliminary immunopurification of PRL samples, conferred good sensitivity and specificity to PRL biological assay. Whenever possible, bioactivity values were correlated with glycosylated-PRL levels (G-PRL), the major posttranslational modification known to reduce PRL bioactivity. The ratio of bioactive (B-) vs immunoreactive PRL (I-PRL) (B/I) in normal subjects was 0.9 ± 0.1 (mean ± SD), and not affected by TRH and sulpiride administration. PRL B/I ratio did not change during pregnancy, both in maternal (0.8 ± 0.1) and fetal circulation (1.0 ± 0.01). In patients with prolactinoma PRL B/I ratios (0.8 ± 0.18) were in the normal range. However, in 2 women with microprolactinoma, with a clear discrepancy between high I-PRL levels and mild clinical features, a significantly reduced PRL B/I ratio was observed (0.51 ± 0.08 and 0.52 ± 0.1 respectively). Conversely, a woman with clear clinical features of hyperprolactinemia, but border-line elevated I-PRL levels had a PRL B/I ratio in the upper limit of normal range. No variation in G-PRL vs NG-PRL percentages was observed in all the cases studied. In conclusion, our data show that physiological and pathological conditions of hyperprolactinemia, including fetal life, are associated in the majority of cases, with the secretion of PRL molecules with unchanged mitogenic activity on Nb2 cells. Nb2 PRL bioassay may be an useful tool to explain the discrepancies between clinical features and immunoreactive PRL levels in some particular cases.

AB - Multiple posttranslational processes modify native PRL and result in the secretion of several PRL isoforms with different bioactivity. Since we observed that serum samples contain non-lactogenic substances able to interfere in Nb2 cell bioassay, in this study we extracted PRL molecules from sera of pregnant and non-pregnant normal adults, fetuses and patients with prolactinoma and evaluated the ability of partially purified PRL to stimulate Nb2 cell proliferation. The preliminary immunopurification of PRL samples, conferred good sensitivity and specificity to PRL biological assay. Whenever possible, bioactivity values were correlated with glycosylated-PRL levels (G-PRL), the major posttranslational modification known to reduce PRL bioactivity. The ratio of bioactive (B-) vs immunoreactive PRL (I-PRL) (B/I) in normal subjects was 0.9 ± 0.1 (mean ± SD), and not affected by TRH and sulpiride administration. PRL B/I ratio did not change during pregnancy, both in maternal (0.8 ± 0.1) and fetal circulation (1.0 ± 0.01). In patients with prolactinoma PRL B/I ratios (0.8 ± 0.18) were in the normal range. However, in 2 women with microprolactinoma, with a clear discrepancy between high I-PRL levels and mild clinical features, a significantly reduced PRL B/I ratio was observed (0.51 ± 0.08 and 0.52 ± 0.1 respectively). Conversely, a woman with clear clinical features of hyperprolactinemia, but border-line elevated I-PRL levels had a PRL B/I ratio in the upper limit of normal range. No variation in G-PRL vs NG-PRL percentages was observed in all the cases studied. In conclusion, our data show that physiological and pathological conditions of hyperprolactinemia, including fetal life, are associated in the majority of cases, with the secretion of PRL molecules with unchanged mitogenic activity on Nb2 cells. Nb2 PRL bioassay may be an useful tool to explain the discrepancies between clinical features and immunoreactive PRL levels in some particular cases.

KW - Fetuses

KW - Glycosylated PRL

KW - Nb2 rat lymphoma cells

KW - Pregnancy

KW - PRL bioactivity

KW - PRL-secreting pituitary adenoma

UR - http://www.scopus.com/inward/record.url?scp=0033223282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033223282&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 225

EP - 231

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 3

ER -